Clinicopathologic Features of Acute Kidney Injury Associated With CDK4/6 Inhibitors

Shruti Gupta1, Tiffany Caza2, Sandra M. Herrmann3, Vipulbhai C. Sakhiya4 and Kenar D. Jhaveri4

1Division of Renal Medicine, Brigham and Women’s Hospital, Boston, Massachusetts, USA; 2Arkana Laboratories, Little Rock, Arkansas, USA; 3Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA; and 4Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, New York, USA

Correspondence: Shruti Gupta, Division of Renal Medicine, Brigham and Women’s Hospital, 75 Francis Street, Boston, Massachusetts 02115, USA. E-mail: sgupta21@bwh.harvard.edu; or Kenar D. Jhaveri, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, New York, USA. E-mail: Kjhaveri@northwell.edu

Received 24 November 2021; accepted 29 November 2021; published online 8 December 2021

Kidney Int Rep (2022) 7, 618–623; https://doi.org/10.1016/j.ekir.2021.11.033
© 2021 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

INTRODUCTION

Selective estrogen receptor inhibitors and aromatase inhibitors are the mainstay of therapy for HR+ breast cancer; however, most metastatic hormonal receptor-positive, HER2—breast cancers progress and acquire resistance to endocrine therapies.1 CDK4/6 inhibitors comprise a new class of drugs that overcome this resistance by blocking the transition from the G1 to the S phase of the cell cycle, thereby preventing cell-cycle progression and cancer growth.2 There were 3 CDK4/6 inhibitors—palbociclib, ribociclib, and abemaciclib—that have been approved for HER2—metastatic breast cancers, usually in combination with hormone therapy. Multiple clinical trials have revealed that CDK4/6 inhibitors increase progression-free survival.3–6

The most common adverse events associated with CDK4/6 inhibitors are neutropenia, leukopenia, and fatigue.3,4,6 Acute kidney injury (AKI) is not a well-described complication, with pharmacologic studies suggesting patients may have a rise in serum creatinine (SCr) without true renal injury.7 Here, we present the first series of patients with biopsy-proven AKI associated with CDK4/6 inhibitors, with a focus on clinical features and pathologic findings.

BRIEF METHODS

All protocols were approved by each hospital’s Institutional Review Board. Cases were obtained by querying nephrology and pathology departments at 2 academic centers (Massachusetts General Hospital, Mayo Clinic, Rochester, MN) and Arkana Laboratories.

Data Collection

Data on age, sex, race, type of malignancy, concomitant medications and chemotherapy, type of CDK4/6 inhibitor, SCr trend before, during, and after AKI, urinalysis findings, urine sediment (when available), renal ultrasound findings, pathology reports and images, and outcomes (e.g., need for renal replacement therapy [RRT], vital status at last follow-up) were collected on each patient by manual chart review.

Definitions

AKI was defined and staged according to the modified Kidney Disease Improving Global Outcomes criteria as a ≥1.5-fold rise in SCr from baseline any time after the drug was started or the need for RRT.8 Baseline SCr was defined as the closest SCr level before CDK4/6 inhibitor initiation. If baseline SCr was unavailable, AKI was defined as a new rise in SCr to >3 mg/dl. The AKI was directly attributed to the CDK4/6 inhibitors by the treating nephrologist, and the patient must have undergone a kidney biopsy because of the AKI. Renal recovery was defined as a nadir SCr ≤1.5 times the baseline value within 90 days after AKI.

Reporting of Renal Adverse Events

The Federal Drug Enforcement Adverse Event Reporting System was queried for kidney adverse events associated with CDK4/6 inhibitors (palbociclib, abemaciclib, and ribociclib) between 2010 and 2020 using the following search terms: hypokalemia, hypomagnesemia, hyponatremia, hypophosphatemia, hypocalcemia, hypercalcemia, hyperkalemia, hypernatremia, hyperphosphatemia, proteinuria, renal
Table 1. Clinical features of CDK4/6 inhibitor-associated AKI

| Pt | Peak SCr | Time to AKI | Admission | UA/sediment | Albuminuria | Renal US |
|----|----------|-------------|-----------|-------------|-------------|----------|
| 1  | 7.0      | NA          | Yes       | +Protein, +blood, 100 WBCs | 1.5         | Cortical echogenicity |
| 2  | 4.0      | NA          | Yes       | +Protein, +protein | 4.5         | NA       |
| 3  | 2.2      | 210         | No        | +Protein, +blood | 0.3         | Normal   |
| 4  | 5.9      | 346         | Yes       | NA           | 0.3         | Cortical echogenicity |
| 5  | 11.2     | 683         | Yes       | +Blood, +protein, granular casts | 1.6         | Cortical echogenicity |
| 6  | 1.9      | 102         | No        | +Blood, +protein, hyaline and muddy brown casts | 5           | Normal   |

AKI, acute kidney injury; LE, leukocyte esterase; NA, not available; Pt, patient; SCr, serum creatinine; UA, urinalysis; US, ultrasound; WBCs, white blood cells.

*Peak SCr during AKI episode, in mg/dl.
*Days from CDK4/6 initiation to AKI.
*Albuminuria at the time of AKI, g/g.

RESULTS

Baseline Characteristics

We identified 6 patients from the Massachusetts General Hospital (n = 1), Mayo Clinic (n = 1), and Arkana Laboratories (n = 4) who had AKI associated with the CDK4/6 inhibitor and underwent a kidney biopsy. Baseline characteristics of each patient are found in Supplementary Table S1. Of 6 patients, 4 were above the age of 65 years. Most patients were White (4 of 6). Two patients had baseline estimated glomerular filtration rate <60 ml/min per 1.73 m². All had metastatic disease at the time of treatment with the CDK4/6 inhibitor.

The most common underlying malignancy was breast adenocarcinoma in 5 of 6 patients (patient 6 had glioblastoma multiforme). Furthermore, 3 of 6 were treated with palbociclib, 2 were treated with abemaciclib, and 1 received ribociclib.

Concomitant Medications and Chemotherapy

There were 2 patients who were using proton pump inhibitors and 1 patient who reported occasional nonsteroidal anti-inflammatory drug use (patient 6) (Supplementary Table S2). Furthermore, 2 patients were prescribed concomitant hormonal therapy (e.g., letrozole) and 2 patients received fulvestrant.

Clinical Features at the Time of AKI

The median time from CDK4/6 initiation to AKI was 278 days (interquartile range 183–430) (Table 1). Patients 2, 4, and 5 each had stage 3 AKI, and patient 5 required RRT. The median SCr at the time of AKI was 2.9 (interquartile range 1.9–5.3). Nephrology was consulted in all cases. None of the patients had hypotension within 72 hours of the AKI event.

At the time of AKI, all patients with urinalyses available had dipstick positive results for protein. Results of renal ultrasound revealed cortical echogenicity in 3 patients. In addition, results of serologic workup (e.g., antinuclear antibody, double-stranded DNA, antinuclear cytoplasmic antibodies, C3, C4, rheumatoid factor, and serum protein electrophoresis) were normal in all patients.

Pathologies

Representative images of kidney biopsies are illustrated in Figure 1. Acute tubular necrosis was the predominant lesion in patients 2 to 6. Patient 5 had marked and widespread tubular injury, characterized by dilation and loss of brush borders, flattened epithelium, focal tubular rupture, and many intratubular casts in the medulla. Patient 1 had acute tubulointerstitial nephritis that was neutrophil rich. A urine culture was performed, and result was positive for Candida species. Nevertheless, the pathology was not suggestive of pyelonephritis; a Grocott’s methenamine silver stain was performed on the biopsy and result was negative for fungal elements. The acute tubulointerstitial nephritis was attributed to the CDK4/6 inhibitor by the treating nephrologist.

Treatment and Outcomes

The CDK4/6 inhibitor was discontinued in patients 1 and 5, and dose was reduced in patients 4 and 6. Patient 5 was subsequently liberated from RRT 6 months after the AKI event. Patient 1 was not treated with corticosteroids as she was transitioned to comfort care and died. Patient 5 was also transitioned to comfort care and passed away. Patient 6 had incomplete recovery of SCr to a nadir of 1.6 approximately 50 days after the AKI event. Patient 4 similarly had incomplete recovery with a nadir SCr of 2.4 within 90 days of the AKI event and had progression of disease with liver involvement. Patients 2 and 3 had limited treatment and follow-up data. No patient received any immunosuppressive treatment for the AKI event.

Reporting of Renal-Related Adverse Events

There were 783 adverse events reported for all 3 agents (palbociclib, abemaciclib, and ribociclib) (Table 2), most often renal injury. Palbociclib had the largest number of adverse events, and these were most frequently reported among females. Metabolic disturbances were reported with all 3 agents, usually failure acute, AKI, elevated creatinine, hypercreatinemia, hypertension, and nephritis.
hypokalemia, though hyponatremia and hypocalcemia were also observed.

**DISCUSSION**

Although CDK4/6 inhibitors have transformed the landscape of therapy for hormonal receptor-positive advanced breast cancer, here we describe 6 patients who had biopsy-proven AKI that was directly attributed to the CDK4/6 inhibitor. AKI had major repercussions, requiring dose reduction and or discontinuation of therapy in 4 of 6 patients. In addition, based on a search of the Federal Drug Enforcement Adverse Event Reporting System database, AKI is a reported complication of CDK4/6 inhibitors, as are metabolic disturbances, such as hypokalemia, hyponatremia, and hypocalcemia. Supplementary Table S3 summarizes previous data and our findings of adverse renal events reported with CDK4/6 inhibitors.

Existing data on AKI from CDK4/6 inhibitors are scant. Several early trials of palbociclib and ribociclib did not describe the incidence of AKI, whereas clinical trials of abemaciclib have reported that up to 25% of patients experienced a rise in SCr. In vitro studies of abemaciclib have revealed that the drug and its major metabolites inhibit renal transporters such as organic cation transporter-2, multidrug and toxin extrusion-1 (MATE-1), and MATE2-K, potentially leading to a reversible rise in SCr without actually changing glomerular filtration.
Nevertheless, in our series, 3 of 6 patients had severe stage 3 AKI with 1 requiring RRT, and each of the 6 patients had biopsy-proven AKI. Differentiating “pseudo-AKI” from true AKI can be challenging. Simultaneous measurement of SCr, kidney iothalamate clearance, and/or estimated glomerular filtration rate (with the caveat that this might be elevated in the setting of inflammation) may help distinguish between the 2 entities. Furthermore, patients with true AKI may have cortical echogenicity on renal ultrasound, though 2 of the patients had normal renal ultrasound results.

The time of onset of AKI was prolonged in relation to use of CDK4/6 inhibitors. It is therefore possible that there was a “second-hit” that predisposed to the development of AKI; however, there was no other identifiable trigger in any of the cases, aside from the CDK4/6 inhibitor. In addition, there are other cancer therapies (e.g., immunotherapy, vascular endothelial growth factor inhibitors) in which there is often a lag time between initiation of the treatment and the onset of AKI. 

The most common histopathologic finding on biopsy was acute tubular necrosis, in the absence of an alternative explanation, such as hypotension, recent i.v. contrast use, or sepsis. The mechanism behind the acute tubular necrosis is unclear, but it may be due to off-target effects of the CDK4/6 inhibitors, with tubular cell damage from the inhibition of cell-cycle progression. Patient 1 had acute tubulointerstitial nephritis, which suggests that there is also the possibility of hypersensitivity reactions to these drugs. Paradoxically, there are preclinical data suggesting CDK4/6 inhibitors may have a nephroprotective effect. Induction of G0/G1 cycle arrest through CDK4/6 inhibition has been found to protect proximal tubular epithelial cells after exposure to nephrotoxins, such as cisplatin, etoposide, and antimycin A.

### Table 2. Renal adverse events associated with CDK4/6 inhibitors from the Food and Drug Administration adverse event reporting system

| Name of medication | Reaction | Male (n = 5), n/N (%) | Female (n = 195), n/N (%) | Missing (n = 10), n/N (%) | Overall (n = 210), n/N (%) |
|--------------------|----------|-----------------------|--------------------------|--------------------------|--------------------------|
| Ribociclib (N = 210) | Renal injury* | 3 (60) | 82 (42) | 8 (80) | 93 (44) |
| Hypokalemia | 1 (20) | 29 (15) | 1 (10) | 31 (15) |
| Hypocalcemia | 1 (20) | 29 (15) | 0 (0) | 30 (14) |
| Hypernatremia | 0 (0) | 31 (16) | 1 (10) | 32 (15) |
| Hyperkalemia | 0 (0) | 9 (5) | 0 (0) | 9 (4) |
| Hypophosphatemia | 0 (0) | 7 (4) | 0 (0) | 7 (3) |
| Hypercalcemia | 0 (0) | 6 (3) | 0 (0) | 6 (3) |
| Hypomagnesemia | 0 (0) | 2 (1) | 0 (0) | 2 (1) |
| Abemaciclib (N = 84) | Renal injury | 1 (100) | 45 (58) | 4 (67) | 50 (60) |
| Hypokalemia | 0 (0) | 16 (21) | 2 (33) | 18 (21) |
| Hypernatremia | 0 (0) | 10 (13) | 0 (0) | 10 (12) |
| Hypercalcemia | 0 (0) | 2 (3) | 0 (0) | 2 (2) |
| Hypocalcemia | 0 (0) | 2 (3) | 0 (0) | 2 (2) |
| Acidosis | 0 (0) | 1 (1) | 0 (0) | 1 (1) |
| Hyperkalemia | 0 (0) | 1 (1) | 0 (0) | 1 (1) |
| Palbociclib (N = 489) | Renal injury | 7 (50) | 279 (59) | 4 (80) | 290 (59) |
| Hypokalemia | 3 (21) | 62 (13) | 0 (0) | 65 (13) |
| Hypernatremia | 3 (21) | 39 (8) | 0 (0) | 42 (9) |
| Hypercalcemia | 1 (7) | 34 (7) | 0 (0) | 35 (7) |
| Hypocalcemia | 0 (0) | 25 (5) | 1 (20) | 26 (5) |
| Hyperkalemia | 0 (0) | 20 (4) | 0 (0) | 20 (4) |
| Hypomagnesemia | 0 (0) | 4 (1) | 0 (0) | 4 (1) |
| Hypophosphatemia | 0 (0) | 4 (1) | 0 (0) | 4 (1) |
| Hypernatremia | 0 (0) | 3 (1) | 0 (0) | 3 (1) |

*Renal injury comprises proteinuria, renal failure acute, acute kidney injury, elevated creatinine, hypercreatinemia, and nephritis.

There are limitations to the Food and Drug Administration adverse event reporting system. The events are reported by providers and/or patients and may therefore be subject to reporting bias. In addition, not all demographic and comorbidity information is available to help identify whether other nephrotoxic risk factors are present (e.g., use of nonsteroidal anti-inflammatory agents, history of hypertension or diabetes mellitus, known chronic kidney disease, recent use of contrast agent, and recent use of chemotherapy with nephrotoxic potential). It is not possible to determine whether an event is truly caused by the drug as opposed to the underlying disease, concomitant medications, or previous chemotherapies administered to these patients. Finally, there is no denominator for the number of patients who received these agents, and therefore, a percent risk of the adverse outcome cannot be computed.
that the duration of exposure to CDK4/6 inhibition matters, whereby transient exposure to cell cycle inhibitors may be protective, yet prolonged exposure may lead to AKI. Furthermore, in advanced breast cancer, mutations can accumulate, with mismatch repair defects that could result in antitumor immune responses driving increased cytokine production and/or leukocyte infiltration.

A search of the Federal Drug Enforcement Adverse Event Reporting System database revealed that, in addition to AKI, metabolic disturbances such as hypokalemia, hyponatremia, and hypocalcemia may occur while on CDK4/6 inhibitors. Hyponatremia has been reported with ribociclib and abemaciclib, S9, S10 and grade 2 hypokalemia was reported in 20.8% of patients taking abemaciclib. S10 Given that CDK4/6 inhibitors are associated with QT prolongation, particularly ribociclib, S11 it is imperative that patients undergo frequent monitoring of serum electrolytes before therapy and with each cycle.

Although our study is the first to describe clinical features and histopathology associated with CDK4/6 inhibitors, there were limitations. We had incomplete follow-up data for 2 patients. In addition, we cannot exclude the possibility that the AKI event was caused by a concomitant medication rather than the CDK4/6 inhibitor. Use of the Federal Drug Enforcement Adverse Event Reporting System database has its limitations as well; it includes all provider and patient-reported adverse events and therefore may not capture true AKI. Furthermore, demographic and comorbidity information is not readily available to determine whether other nephrotoxic risk factors may be contributing.

Although CDK4/6 inhibitors may lead to a reversible rise in SCR without actually changing glomerular filtration rate in some cases, we now reveal that they can also cause true renal tubular toxicity. Given the relative novelty of CDK4/6 inhibitors, there is much that remains unknown on the mechanism behind AKI associated with these drugs. Larger, prospective studies are needed to understand and characterize the incidence of and risk factors for AKI in patients receiving CDK4/6 inhibitors.

**ACKNOWLEDGMENTS**

SG reports receiving research funding from GE HealthCare and BTG International.

SMH is funded by the National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases (K08 DK118120).

**SUPPLEMENTARY MATERIAL**

Supplementary File (PDF)

Table S1. Baseline characteristics.

Table S2. Medications at the time of CDK4/6 inhibitor-associated AKI.

Table S3. Summary of renal adverse events associated with CDK4/6 inhibitors.

**Supplementary References.**

**REFERENCES**

1. Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. *Annu Rev Med*. 2011;62:233–247. https://doi.org/10.1146/annurev-med-070909-182917

2. Finn RS, Aleshin A, Slamon DJ. Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers. *Breast Cancer Res*. 2016;18:17. https://doi.org/10.1186/s13058-015-0661-5

3. Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in hormone-receptor-positive, HER2-negative metastatic breast cancer. *N Engl J Med*. 2016;375:1925–1936. https://doi.org/10.1056/NEJMoa1607303

4. Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer [published correction appears in *N Engl J Med*. 2018;379:2582]. *N Engl J Med*. 2016;375:1738–1748. https://doi.org/10.1056/NEJMoa1609709

5. Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy [PALOMA-3]: final analysis of the multicentre, double-blind, phase 3 randomised controlled trial [published correction appears in *Lancet Oncol*. 2016;17:e136 and *Lancet Oncol*. 2016;17:e270]. *Lancet Oncol*. 2016;17:425–439. https://doi.org/10.1016/S1470-2045(15)00613-0

6. Sledge GW, Toi M, Neven P, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2-advanced breast cancer who had progressed while receiving endocrine therapy. *J Clin Oncol.*
7. Chappell JC, Turner PK, Pak YA, et al. Abemaciclib inhibits renal tubular secretion without changing glomerular filtration rate. *Clin Pharmacol Ther*. 2019;105:1187–1195. https://doi.org/10.1002/cpt.1296

8. Kellum JA, Lameire N, Aspelin P, et al. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. *Kidney Int Suppl*. 2012;2:1–138.

9. Sledge GW, Toi M, Neven P, et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy - MONARCH 2: a randomized clinical trial. *JAMA Oncol*. 2020;6:116–124. https://doi.org/10.1001/jamaoncol.2019.4782